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Background: Apparently balanced chromosomal rearrangements can be associated with an abnormal phenotype,
including intellectual disability and autism spectrum disorder (ASD). Genome-wide microarrays reveal cryptic genomic
imbalances, related or not to the breakpoints, in 25% to 50% of patients with an abnormal phenotype carrying a
microscopically balanced chromosomal rearrangement. Here we performed microarray analysis of 18 patients with ASD
carrying balanced chromosomal abnormalities to identify submicroscopic imbalances implicated in abnormal
neurodevelopment.
Methods: Eighteen patients with ASD carrying apparently balanced chromosomal abnormalities were screened
using single nucleotide polymorphism (SNP) arrays. Nine rearrangements were de novo, seven inherited, and
two of unknown inheritance. Genomic imbalances were confirmed by fluorescence in situ hybridization and
quantitative PCR.
Results: We detected clinically significant de novo copy number variants in four patients (22%), including three
with de novo rearrangements and one with an inherited abnormality. The sizes ranged from 3.3 to 4.9 Mb;
three were related to the breakpoint regions and one occurred elsewhere. We report a patient with a
duplication of the Wolf-Hirschhorn syndrome critical region, contributing to the delineation of this rare
genomic disorder. The patient has a chromosome 4p inverted duplication deletion, with a 0.5 Mb deletion of
terminal 4p and a 4.2 Mb duplication of 4p16.2p16.3. The other cases included an apparently balanced de novo
translocation t(5;18)(q12;p11.2) with a 4.2 Mb deletion at the 18p breakpoint, a subject with de novo pericentric
inversion inv(11)(p14q23.2) in whom the array revealed a de novo 4.9 Mb deletion in 7q21.3q22.1, and a patient
with a maternal inv(2)(q14.2q37.3) with a de novo 3.3 Mb terminal 2q deletion and a 4.2 Mb duplication at the
proximal breakpoint. In addition, we identified a rare de novo deletion of unknown significance on a
chromosome unrelated to the initial rearrangement, disrupting a single gene, RFX3.
Conclusions: These findings underscore the utility of SNP arrays for investigating apparently balanced
chromosomal abnormalities in subjects with ASD or related neurodevelopmental disorders in both clinical and
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Balanced chromosome abnormalities, including transloca-
tions and inversions, are structural rearrangements of gen-
etic material with no overall gain or loss detected with
conventional karyotyping. Apparently balanced chromo-
somal rearrangements (ABCR) have an estimated fre-
quency of 0.5% in newborns [1], including 14% de novo.
About 6% of de novo ABCR detected at amniocentesis are
associated with an abnormal phenotype, including intellec-
tual disability (ID) and multiple congenital anomalies [2].
Because of the insufficient discrimination power of con-
ventional cytogenetics, in which genomic imbalances
smaller than 5 to 10 megabases (Mb) are usually not de-
tected, the most common explanation for the clinical ab-
normalities is cryptic loss or gain of genomic material at or
in the vicinity of the breakpoint. When there is no loss or
gain of DNA sequences, the rearrangement can disrupt a
dosage-sensitive gene, separate a gene from its cis regula-
tory elements, or generate a functional chimeric gene.
Studies using DNA microarray technologies have dem-
onstrated submicroscopic anomalies related or not to the
breakpoint in 46% (range 31% to 100%) of patients with an
abnormal phenotype carrying a de novo ABCR [3-10].
Inherited ABCR in patients with an abnormal phenotype
have been studied less often, but they can also be associ-
ated with cryptic imbalances at the breakpoint or elsewhere
in the genome, with a combined frequency of 25% (6/24)
in three studies [7-9]. Imbalances are more frequent in
complex rearrangements involving more than two break-
points and in patients with a complex phenotype [10]. In
contrast, genomic imbalances are unlikely to be detected
in phenotypically normal carriers of apparently balanced
translocations [6]. Taken together, these findings indicate
that a significant proportion of ABCR in phenotypically ab-
normal individuals are in fact associated with genomic im-
balances and that these rearrangements should be
systematically investigated by high-resolution microarrays
independently of their de novo or inherited origin. The
phenotypes of the patients in previous studies were very
heterogeneous, including developmental delay, ID, multiple
congenital anomalies, and autism spectrum disorder
(ASD).
ASD is an etiologically heterogeneous neurodevelopmen-
tal disorder characterized by impairments in social com-
munication and by restricted interests and stereotyped
behaviors. Hundreds of rare variants, including chromo-
somal abnormalities, copy number variants (CNVs), and
single nucleotide variants have been implicated in ASD
[11,12]. However, for about 80% of cases, the underlying
genetic determinants remain unknown. The frequency of
structural chromosomal imbalances detected by conven-
tional cytogenetics in autism varies between 2% and 6%
[13,14], including karyotypically balanced chromosomal
abnormalities. To date, only isolated cases with ABCR andASD have been studied by array technology (for example
[15,16]). Here we report a series of 18 patients with ASD
carrying de novo or inherited ABCR studied by single nu-
cleotide polymorphism (SNP) arrays to identify cryptic
CNVs implicated in abnormal neurodevelopment.
Methods
Subjects
Patients with ASD and ABCR were ascertained through two
sources: 1) 12 patients from the Paris Autism Research
International Study (PARIS) family dataset [17], and 2) 6 pa-
tients referred by the network of French cytogeneticists. A
summary of the clinical and cytogenetic data of the patients
is shown in Table 1. Sixteen patients fulfilled DSM-IV cri-
teria for autistic disorder, while two subjects (patients 9 and
13) had a previous diagnosis of ASD but could not be for-
mally evaluated for ASD for this study. The Autism Diag-
nostic Interview-Revised (ADI-R) was performed in 14
subjects; in 1 individual, the Diagnostic Interview for Social
and Communication Disorders, tenth revision (DISCO-10)
was used instead. In addition, five subjects were assessed
with the Autism Diagnostic Observation Schedule (ADOS).
Fourteen patients had ID. Based on the presence of facial
dysmorphism and/or malformations, six subjects were con-
sidered to have syndromic ASD (patients 3, 4, 5, 9, 10, and
15). Fragile X molecular testing and metabolic screening
were normal in all individuals. All parents were phenotypic-
ally normal, including those carrying a rearrangement. The
study was performed in accordance with the ethical stan-
dards of the responsible institutional and national commit-
tees on human experimentation, in compliance with the
Helsinki Declaration. Informed consent was obtained from
all families participating in the study. For the PARIS pa-
tients, the study was approved by the research ethics boards
of the collaborating institutions (Comité de Protection des
Personnes Ile-de-France VI, Paris, France, and Ethical Re-
view Board in Gothenburg, Sweden).
Conventional cytogenetic analysis
Karyotype (G-banded and/or R-banded, 450 band level)
showing an ABCR was available for all patients and in most
of the parents before inclusion. The sample included ten
autosomal reciprocal translocations, one X-autosome trans-
location, three rare inversions, and four common pericentric
inversions of chromosomes 2, 5, 9, and Y, usually considered
as cytogenetic variants (Table 1). Nine chromosomal rear-
rangements were de novo, four were maternally inherited,
three were paternal, and in two cases, the inheritance could
not be defined because no blood samples were available
from the fathers.
Whole-genome SNP array
SNP array analysis was performed in affected individuals
and their parents using the Human CNV370-Duo DNA
Table 1 Clinical and cytogenetic characteristics of patients
Patient Initial
karyotype
Sex Age at
last
evaluation
ASD Cognitive
level
Language Birth and early
development
Body measures Dysmorphic features Other Brain MRI
1a 46,XY,der(4)t
(4;acro p)
(p16.3;acro
p)dn
M 4 y Autism
(DISCO)
VIQ 67, PIQ
78, FSIQ 69
(WPPSI-R,
34 mo)
Functional
language
Born at 42 wk,
W +4.3 SD (gestational
diabetes), neonatal
hypoglycemia. Normal
motor milestones
4 y: W and
H +2-3 SD
No dysmorphic
features, mild
strabismus
Inguinal hernia Not done
2a 46,XY,t(5;18)
(q12;p11.2)
dn
M 5 y Autism
(ADI-R)
DQ 52
(PEP-R, 40
mo)
1st words
36 mo, no
sentences
Born at 38 wk, W –
0.6 SD, H –1 SD,
OFC mean. Walked
at 17 mo
5 y: W –1 SD,
H +1 SD,
OFC –0.4 SD
No dysmorphic
features, slender
habitus, long
fingers and toes,
numerous secondary
palmar creases
Frequent otitis,
eczema
Small bilateral
insular
hypersignal
suggesting
myelinization
delay (at 4 y)
3b 46,XY,inv(11)
(p14q23.2)
dn
M 4 y Autism
(ADI-R,
ADOS)
DQ 13 mo
(Brunet
Lezine-R, 4 y)
Non-verbal Intrauterine growth
retardation, born at
37 wk, W –3.5 SD,
H –3.5 SD, OFC –2.5
SD. Delayed motor
development,
unable to walk
at 4 y
42 mo: W, H
and OFC –3
SD
Mild dysmorphic
features, high
forehead, horizontal
eyebrows, upslanting
palpebral fissures,
bulbous nose, smooth
philtrum, thin upper
lip, posteriorly rotated
ears, single palmar
crease, bilateral
clinodactyly 5th
finger
Aggressiveness,
anxiety, stereotypies,
head banging, bilateral
cryptorchidism, axial
hypotonia, hyperlaxity
Supratentorial
ventricular
enlargement,
increased
subarachnoid
spaces
(at 18 mo)
4a 46,XY,inv(2)
(q14.2q37.3)mat
(reported
previously
[15])
M 14 y Autism
(ADI-R)
VIQ 46, PIQ
50, FSIQ 46
(WISC-III, 14 y)
1st words
30 mo, 1st
sentences
60 mo
Born at 39 wk,
W mean, H –0.5 SD,
OFC –1.1 SD. Sat at
9 mo, walked at 14
mo
12 y: W +0.5
SD, H –0.5 SD,
OFC mean
Mild dysmorphic
features, frontal
bossing, flattened nasal
bridge, deep-set eyes,
downslanting palpebral
fissures, thin upper lip
Hyperactivity, head
banging, anxiety,
asthma, insulin-
dependent diabetes,
growth hormone
deficit
Normal (at 3 y)
5a 46,XX,inv(2)
(p12q14.1)
dn (benign
cytogenetic
variant)
F 13 y Autism
(ADI-R)
DQ 30
(PEP-R, 6 y)
Non-verbal Born at 39 wk,
W +0.5 SD, H mean,
OFC +1.9 SD. Sat at
normal age, walked
at 22 mo
13 y: W +3.5
SD, H +2 SD,
macrocephaly
(+4.2 SD)
Mild dysmorphic
features, narrow
palpebral fissures,
short philtrum, large
hands and feet,
one café-au-lait spot
Stereotypies,
self-injurious
behavior, sleep
disturbance, one
episode of febrile
seizure at 31 mo,
normal EEG
Chiari type I
malformation,
mild white matter
hyperintensities
(at 9 y)
6a 46,XX,inv(9)
(p11q13)dn
(benign
cytogenetic
variant)
F 7 y Autism
(ADI-R)
Intellectual
disability
Isolated
words
Born at term,
W +0.5 SD, H +0.9 SD.
Walked at 12 mo
7 y 2 mo:
W +3.8 SD,
H +4.1 SD,
OFC +1.7 SD
No dysmorphic
features
Precocious puberty
at 7 y, bone age 8 y,
normal hormone
levels, pulmonar
stenosis, moderate
systolic murmur
Normal (at 7 y)
7a 46,XY,inv(5)
(q13q34)dn
M 18 y Autism
(ADI-R)
VIQ 93, PIQ
80, FSIQ 86
(WISC-III, 18 y)
No delay,
functional
language
Born at 40 wk, mean
W, H and OFC. Sat
at 9 mo, walked at
20 mo
18 y: W –1.4
SD, H mean,
OFC +1.6 SD
No dysmorphic
features,
mild clubbing
Refraction error Myelinization
delay (at 18 y)
8b 46,XY,t(9;19)
(p12;q13.4)dn
M 7 y Autism
(ADI-R,
ADOS)
VIQ 83, PIQ
80, FSIQ 79
(WPPSI, 5 y 5 mo)
1st words
24 mo, 1st
sentences 36 mo,
functional
language
Born at term, W +1
SD, OFC +0.3 SD. Sat
at 7 mo, walked
at 11 mo
NA No dysmorphic
features
ADHD Normal
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Table 1 Clinical and cytogenetic characteristics of patients (Continued)
9b 46,XX,t(X;5)
(p11.2;q35.2)dn
(reported
previously [59])
F 8 y ASDc PIQ 58 (WISC-R
at 8 y)
Non-verbal, uses
sign language
Born at term,
W +1 SD. Sat at 9 mo,
walked at 21 mo
4 y: W and
H mean, OFC +1 SD
Mild dysmorphic
features, prominent
forehead, saddle
nose, midface
hypoplasia, high
arched palate,
generalized
alopecia with
scattered thin hair,
umbilical hernia,
pectus excavatum
Hypomelanosis of Ito,
pigmented lesions on
the legs, achromic
lesion on the back, hypotonia,
hyperlaxity, flat feet,
hypermetropia, febrile
seizures, absence
seizures, abnormal EEG.
Skewed X inactivation of the
normal chromosome (92%)
Normal (at 6 y)
10a 46,XY,t(20;21)
(q11.2;q21)dn
M 12 y Autism
(ADI-R)
DQ 20 (PEP-R,
12 y)
Non-verbal Born at 41 wk,
W –1.7 SD, H –0.5 SD,
OFC –1.1 SD. Sat at
9 mo, walked at
18 mo
12 y: W –1.8 SD,
H mean, microcephaly
(–3.6 SD)
Dysmorphic features,
low forehead, thick
eyebrows, l
ong nose, short
philtrum, right
single transverse
palmar crease
Strabismus, epilepsy
(onset at 9 mo)
Not done
11a 46,XY,t(9;16)
(q3.2;p1.2)mat
M 18 y Autism
(ADI-R)
VIQ 46, PIQ 46,
FSIQ 40 (WISC-III,
14 y)
Language delay,
1st phrases
5 y, functional
language
Born at term, W +1.3
SD, H +1 SD,
OFC +2.1 SD. Sat at 8 mo,
walked at 14 mo
18 y: W +3 SD,
H mean, OFC +2.3 SD
No dysmorphic
features, short neck,
brachymetatarsia
of 4th and 5th rays
Hyperactivity in childhood,
strabismus, hypermetropia
Not done
12a 46,XY,t(3;8)
(q13.2;p23)mat
M 5 y Autism
(DSM-
IV,
CARS)
VIQ 79, PIQ 74,
FSIQ 77
(Stanford-Binet
IV, 3 y 9 mo)
1st words 26 mo,
1st sentences 36 mo,
few sentences at 5 y,
dysarthric speech
Normal pregnancy,
delivery and
early development;
walked at 13 mo
4 y: W, H and OFC
within normal limits
No dysmorphic
facial features,
long ring finger,
brachymesophalangia
V, sandal gap
Severe ADHD, pica,
self-injurious
behavior, partial complex
epilepsy (onset at 4 y,
currently seizure free on
medication), chronic ear
infections, chronic diarrhea,
food allergies
Not done
13b 46,XY,t(2;20)
(q13;q13.33)mat
M 22 y ASDc Intellectual
disability
Language delay,
uses only
a few words,
answers with signs
Born at term, W –0.8
SD, H –1 SD,
OFC –1.1 SD. Sat at 11
mo, walked at 2 y
22 y: W +1.4 SD, H
mean, OFC –1 SD
No dysmorphic facial
features, bilateral
clinodactyly 5th
finger, several café au
lait spots
Hyperactivity, aggressiveness,
inappropriate laughter,
hand stereotypies, unilateral
strabismus, seizures at 7 mo,
no recurrence after
stopping treatment
Normal (at 1 y)
14a 46,XX,inv(5)
(p13.3q13.3)pat
(benign
cytogenetic
variant)
F 8 y Autism
(ADI-R)
DQ 55 (PEP-R,
5 y)
1st words 18 mo, 1st
sentences before 3 y;
echolalic language
Dizygotic twin
pregnancy,
born at 27 wk,
W 880 g.
Walked at 18 mo
8 y: W mean, H
and OFC +1 SD
No dysmorphic
features, long
face, flat feet, tuberous
angioma scar on
scapula
Insensitivity to pain Non specific
white matter
hypersignal
(at 5 y)
15a 46,X,inv(Y)
(p11q11)pat
(benign
cytogenetic
variant)
M 14 y Autism
(ADI-R)
DQ 15 (PEP-R,
14 y)
Non-verbal Born at 38 wk,
W –2.1 SD,
H –1.5 SD, OFC
–2 SD. Sat at
9 mo, walked
at 13 mo
14 y: W +2 SD,
H +1 SD, OFC mean
Synophris, abnormal
dental implantation
(delayed tooth loss)
Normal (at 14 y)
16b 46,XY,t(2;13)
(p23;q14)pat
M 7 y Autism
(ADI-R,
ADOS)
PIQ <1st %ile
(Raven, 7 y
5 mo)
1st words 36 mo,
1st sentences 48
mo, functional
language
Born at term,
W –1.2 SD,
H +0.5 SD, OFC
+0.7 SD. Sat at
20 mo, walked
at 36 mo
NA No dysmorphic
features
ADHD Normal
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Table 1 Clinical and cytogenetic characteristics of patients (Continued)
17a 46,XY,t(4;9)
(p13;p23)
(not maternal,
father not tested)
M 30 y Autism
(ADI-R,
ADOS)
DQ <20
(PEP-R, 16 y)
Non-verbal Born at term,
W +0.7 SD,
H +1 SD. Feeding
difficulties,
hypotonia,
growth delay
(–3 SD). Walked
at 4 y
30 y: W –1
SD, H +1.1
SD, OFC –0.5 SD
No dysmorphic features
except for enophtalmia,
low-set eyebrows,
large ears, narrow
hands
Hyperactivity, severe
sleep disturbance,
insensitivity to pain,
gastric and
esophageal ulcers,
abnormal EEG at 1 y
(temporal lobe focus),
no epilepsy
Not done
(encephalography
at 6 mo: global
ventricular
dilatation)
18b 46,XY,t(2;13)
(q22;q31)
(not maternal,
father not tested)
M 4 y Autism
(ADI-R,
ADOS)
IQ <1st %ile
(Raven, 4 y
8 mo)
Non-verbal Born post-term
at 47 wk,
W –0.8 SD,
H –0.8 SD,
OFC –0.6 SD.
Sat at 20 mo,
walked at 36 mo
4 y: W and
H –0.5 SD,
OFC –2 SD
No dysmorphic features,
brachyplagiocephaly
ADHD,
aggressiveness,
anxiety
Normal
aPatients from the PARIS cohort; bpatients referred by the network of French cytogeneticists; cASD was not formally evaluated in these two patients. ADHD, attention deficit-hyperactivity disorder; ADI-R, Autism Diagnostic
Interview-Revised; ADOS, Autism Diagnostic Observation Schedule; ASD, autism spectrum disorder; CARS, Childhood Autism Rating Scale; DISCO, Diagnostic Interview for Social and Communication Disorders; dn,
de novo; DQ, developmental quotient; FSIQ, full scale IQ; H, height; IQ, intellectual quotient; mat, maternal; mo, months; MRI, magnetic resonance imaging; NA, not available; OFC, occipitofrontal circumference; pat,
paternal; PEP-R, Psychoeducational Profile Revised; PIQ, performance IQ; SD, standard deviation; VIQ, verbal IQ; W, weight; WISC-III, Wechsler Intelligence Scale for Children, third edition; WISC-R, Wechsler
Intelligence Scale for Children-Revised; wk, weeks; WPPSI-R, Wechsler Preschool and Primary Scale of Intelligence Revised; y, years.
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three cases, parental DNA was not available (patients 8,
9, and 18), and in one case, only the mother was avail-
able (patient 17). The array contains more than 370,000
markers, with a mean resolution of 30 kb. Genomic
DNA was processed according to the Infinium II assay
manual. SNP copy numbers (log R ratio) and B allele fre-
quencies were assessed using the Bead Studio software
version 3.2, with the CNV partition algorithm, V 1.3.2 or
2.4.4 (Illumina). All genomic coordinates are based on
GRCh37/hg19. The clinical relevance of CNVs was inter-
preted according to the American College of Medical
Genetics guidelines [18].
FISH analyses
Fluorescence in situ hybridization (FISH) analysis was
carried out using specific bacterial artificial chromo-
somes (BACs) to confirm CNVs larger than 1 Mb. BAC
clones were hybridized on metaphase spreads of patients
and their parents, in order to confirm the inheritance.
qPCR
Real-time quantitative PCR (qPCR) was used to confirm
and map CNVs smaller than 1 Mb. For patient 2, qPCR
was used to confirm a larger CNV because metaphase
spreads were not available. We used the Universal Probe
Library (UPL) system (Roche, Indianapolis, IN, USA)
and a LightCycler 480 real-time PCR system (Roche), as
described previously [19].
Results
In this study, 18 patients with ASD and an apparently
balanced chromosome rearrangement were analyzed for
submicroscopic imbalances using genome-wide SNP ar-
rays (Table 1). The microarray analysis detected clinic-
ally significant de novo CNVs in 4/18 patients (22%),
including 3/9 with de novo ABCR and 1/7 with an inher-
ited abnormality (Table 2). Patients 1 and 4 had both a
deletion and a duplication in the chromosome impli-
cated in the rearrangement. Patient 2 had a deletion at
one of the translocation breakpoints, whereas patient 3
carried a deletion on a chromosome unrelated to the
known rearrangement. The size of the pathogenic CNVs
ranged from 3.31 to 4.93 Mb. In addition, patient 5 car-
ried a de novo deletion on a chromosome unrelated to
the initial rearrangement and disrupting a single gene,
RFX3. In the remaining 13 patients, no clinically relevant
rearrangement was detected. None of the patients had
long contiguous stretches of homozygosity involving
multiple chromosomes.
Patient 1
This boy was referred for evaluation at the age of 2 years
and 9 months because of developmental delay and ASDfeatures. He is the second child of healthy non-
consanguineous parents (maternal age 31 years, paternal
age 38 years). He was born at 42 weeks after an unevent-
ful pregnancy, weighing 5,280 g (+4.3 SD), probably due
to latent diabetes in the mother. He was hypoglycemic
during the first days of life, and an inguinal hernia was
corrected at the age of two months. There was no delay
in motor milestones or language development. He was
diagnosed with autism after formal testing at an autism
referral center. He had a borderline IQ of 69 (verbal IQ
67, performance IQ 78). There was no history of sei-
zures, and his EEG was normal. His physical and neuro-
logical exams were normal except for mild strabismus;
in particular, he had no dysmorphic features. At the age
of 4 years, he was +2 SD to +3 SD in weight and height.
Conventional karyotyping showed a de novo transloca-
tion between the telomeric region of the short arm of
chromosome 4 and the short arm of an acrocentric
chromosome. His karyotype was 46,XY,der(4)t(4;acro p)
(p16.3;acro p)dn. Although this translocation is unbal-
anced, this patient was included in the present study be-
cause the excess of heterochromatic material from an
acrocentric short arm cannot explain his abnormal
phenotype. SNP array analysis revealed a 541 kb deletion
in 4p16.3 (17,764-558,839, hg19) and a 4.24 Mb duplica-
tion in 4p16.2p16.3 (577,581-4,812,859) in the proband
(Figure 1A), absent from the parents. Both rearrange-
ments were confirmed by qPCR and FISH. The deletion
was confirmed by FISH with the 4p subtelomeric probe
RP11-2H3. Using probes RP11-296G16 (4p16.3) and
RP11-265012 (4p16.2), the FISH findings were consist-
ent with an inverted duplication (data not shown), indi-
cating a chromosome 4p inverted duplication deletion.
SNP genotyping indicated that both rearrangements oc-
curred on the paternal chromosome. The deletion in-
cludes eight RefSeq genes; the duplication encompasses
70 genes and overlaps the Wolf-Hirschhorn critical re-
gion (Figure 2).
Patient 2
The patient is a 5-year-old boy presenting with non-
syndromic autism and mild ID. He is the second child of
healthy non-consanguineous parents (maternal age 26 years,
paternal age 36 years); antenatal and postnatal periods were
uneventful. His language was delayed; he said his first words
at 36 months and did not use sentences. He was diagnosed
with autism following evaluation at the autism unit of a uni-
versity hospital; he met criteria for autism according to the
ADI-R. He suffered from recurrent otitis media in childhood
and eczema. No dysmorphic features were noticed, except
for long fingers and toes and numerous secondary palmar
creases. Physical and neurological exams were normal. The
original karyotyping showed a de novo, apparently balanced
reciprocal translocation, 46,XY,t(5;18)(q12;p11.2)dn.ish t
Table 2 De novo abnormalities detected by SNP array
Patient Initial karyotype Imbalance Chromosomal region Starta Enda Size (bp) Parental origin
Patients with clinically significant abnormalities
1b 46,XY,der(4)t(4;acro p)(p16.3;acro p)dn Deletion 4p16.3 17,764 558,839 541,076 Paternal
Duplication 4p16.2p16.3 577,581 4,812,859 4,235,279 Paternal
2 46,XY,t(5;18)(q12;p11.2)dn Deletion 18p11.22p11.31 5,408,997 9,625,750 4,216,754 Maternal
3 46,XY,inv(11)(p14q23.2)dn Deletion 7q21.3q22.1 97,043,362 101,977,945 4,934,584 Paternal
4c 46,XY,inv(2)(q14.2q37.3)mat Deletion 2q37.3 239,735,269 243,044,147 3,308,879 Maternal
Duplication 2q14.1q14.2 117,072,756 121,304,548 4,231,793 Maternal
Variant of unknown clinical significance
5 46,XX,inv(2)(p12q14.1)dn Deletion 9p24.2 3,334,203 3,513,286 179,084 Paternal
aGenomic position in hg19 coordinates; bin patient 1, the 4p duplication is pathogenic; the deletion is considered benign; cin patient 4, the 2q37 deletion is
pathogenic; the clinical significance of the duplication is unknown.
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4.22 Mb deletion of chromosome 18p11.22p11.31
(5,408,997-9,625,750) (Figure 1B), originating on the
maternally inherited chromosome. The deletion was
confirmed by qPCR. Both parents had a normal array
profile and normal gene dosage by qPCR.
Patient 3
This boy is the first child of non-consanguineous healthy
European parents (maternal age 32 years, paternal age
31 years) with unremarkable family history. Increased nu-
chal translucency was observed at 12 weeks of gestation.
The amniocentesis karyotype was considered normal. At
22 weeks, an ultrasound revealed bilateral ectopic testes
and dilated colon, and intrauterine growth retardation was
noted at 32 and 36 weeks. He was delivered by cesarean
section at 37 weeks because of fetal heart deceleration. He
was transferred to the neonatal resuscitation unit, venti-
lated for 20 min, and placed in an incubator. Birth weight
was 1,850 g (<5th centile), length 43 cm (<5th centile), and
occipitofrontal circumference (OFC) 32.5 cm (<25th cen-
tile). Tests for congenital infections were negative. After
10 days, he was discharged with sequelae of congenital
muscular torticollis. Feeding difficulties, axial hypotonia,
and hyperlaxity were reported during the first months of
life. At 10 months, his weight and length were below −2
SD, and his OFC decreased at −3 SD. His language devel-
opment and motor milestones were delayed; he was able to
stand up with support at 42 months and did not walk or
talk at 4 years. When examined at the age of 42 months,
his growth parameters remained at −3 SD. Dysmorphic
features included high forehead, horizontal eyebrows,
upslanting palpebral fissures, bulbous nose, smooth phil-
trum, thin upper lip, posteriorly rotated ears, single palmar
crease, and bilateral clinodactyly of the fifth finger. Brain
MRI showed ventricular enlargement and increased frontal
subarachnoid spaces, suggesting global cerebral atrophy.
The EEG and visceral and heart ultrasounds were normal.
He was referred to a child psychiatry unit at the age of4 years, where he received a diagnosis of autism based on
DSM-IV criteria and confirmed by the ADI-R and ADOS.
Evaluation with the Brunet-Lezine Revised Scale showed a
developmental age of 13 months, indicating severe cogni-
tive impairment. The Vineland Adaptive Behavior Scales
showed developmental ages between 9 months (language)
and 18 months (socialization). High-resolution karyotype
revealed a de novo pericentric inversion of chromosome
11: 46,XY,inv(11)(p14q23.2)dn. The SNP array detected no
imbalance on chromosome 11 but showed a de novo
7q21.3q22.1 deletion of 4.93 Mb (97,043,362-101,977,945)
(Figure 1C), occurring on the paternal allele. The deletion
was confirmed by FISH with BACs targeting 7q22.1
(RP11-44M6 and DBACA-20A02, Integragen, Evry,
France) and excluded in the parents.
Patient 4
The clinical and genetic characterization of this 14-year-old
male was reported previously [15]. Briefly, he is the second
child of a non-consanguineous healthy couple (maternal age
26 and paternal age 31 years) and presented with autism, ID,
insulin-dependent diabetes, growth hormone deficiency, and
mild dysmorphic features (Table 1). Standard karyotype
showed an apparently balanced paracentric inversion of the
long arm of chromosome 2 inherited from his healthy
mother: 46,XY,inv(2)(q14.2q37.3)mat. Array analysis showed
a 3.31 Mb terminal 2q deletion (239,735,269-243,044,147) at
the distal breakpoint of the inversion and a 2q14.1q14.2 du-
plication spanning 4.23 Mb (117,072,756-121,304,548) at the
proximal breakpoint (Figure 1D). Both imbalances occurred
on the maternally derived chromosome and were confirmed
by qPCR. FISH analysis revealed that the duplicated material
was located at the telomeric end of chromosome 2, distal to
the inverted region [15]. Both parents had normal SNP array
profiles. The terminal deletion results in the 2q37 deletion
syndrome, also known as brachydactyly mental retardation
syndrome. Brachydactyly, reported in approximately 50% of
affected individuals [20], was not observed clinically in pa-
tient 4.
Figure 1 (See legend on next page.)
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Figure 1 SNP arrays of patients with clinically significant findings. (A) Patient 1 (46,XY,der(4)t(4;acro p)dn) has a copy number loss of 541 kb
in 4p16.3 and a gain of 4.29 Mb in 4p16.2p16.3. The distal deleted and duplicated 4p segments are shown in detail below. (B) Patient 2 (t(5;18)
(q11.2;p11.2)dn) has deletion of 4.21 Mb in 18p11.31p11.22. (C) Patient 3 (46,XY,inv(11)(p14q23.2)dn) had no imbalance on chromosome 11 but
the SNP array revealed a de novo deletion of 4.3 Mb in 7q21.3q22.1. (D) Patient 4 (46,XY,inv(2)(q14.2q37.3)mat) has a maternally inherited
paracentric inversion of chromosome 2q, with a 2q14.1q14.2 duplication of 4.2 Mb at the proximal breakpoint, and a 2q37.3 deletion of 3.5 Mb
extending to the telomere.
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This female was referred at the age of 4 years and 8 months
because of developmental delay, autistic behavior, and
speech delay and diagnosed with autism after formal test-
ing. She was born at term after an uneventful pregnancy,
with weight and height in the normal range and OFC +1.9
SD. The parents were non-consanguineous; parental ages
at the time of birth were 27 and 28 years for the mother
and father, respectively. She walked at 22 months. At
3 years, she exhibited overgrowth, with height +3 SD and
macrocephaly (+3 SD). Assessment of cognitive function-
ing at 6 years indicated severe ID. When re-evaluated at
11 years, she met criteria for autism according to the ADI-
R, and the Vineland Adaptive Behavior Scales indicated de-
velopmental ages between 14 months (communication and
socialization) and 37 months (motor skills). At the age
of 13 years, all her growth parameters were increased
(weight +3.5 SD, height +2 SD, OFC +4.2 SD), and she
remained non-verbal. She had mild dysmorphic features, in-
cluding narrow palpebral fissures, and short philtrum; her
hands and feet were large, and a café-au-lait spot wasFigure 2 Duplication of the Wolf-Hirschhorn region in patient 1. Map
detected in patient 1 and previously reported overlapping rearrangements
two proposed critical regions (WHSCR1 and WHSCR2) are represented. Hor
deletions. RefSeq genes are indicated at the bottom of the map.present on a toe. A brain MRI performed at 9 years showed
a Chiari malformation type 1 and mild hyperintensities of
the white matter. The macrocephaly prompted screening
for mutations and deletions in PTEN, with normal results
[21]. The standard karyotype was 46,XX,inv(2)(p12q14.1)dn,
which is considered a polymorphic cytogenetic variant. SNP
array analysis revealed a de novo intragenic deletion of
179 kb in the RFX3 gene at 9p24.2 (3,344,203-3,513,286),
on the paternal allele. qPCR confirmed a deletion of exons 2
to 4 of RFX3 in the patient and was normal in both parents.
Discussion
We identified de novo genomic imbalances in 5/18 patients
with ASD and ABCR, of which four were considered
pathogenic (4/18, 22%) and one of unknown clinical sig-
nificance. If we exclude the four patients carrying common
pericentric inversions, which a priori are not expected
to be causative of the phenotype, the yield increases to
33% (4/12). This is in accordance with a previous study
showing that 24% of patients with abnormal phenotype
and a de novo two-point chromosome rearrangementof chromosome 4 (1-6,000,000, hg19) showing the rearrangement
. The region commonly deleted in Wolf-Hirschhorn syndrome and the
izontal blue lines represent duplications, and red lines indicate
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[10]. Three imbalances were related to the breakpoint
regions, and two deletions occurred on unrelated chromo-
somes. In two patients, the SNP array analysis identified a
terminal deletion and a duplication occurring on the same
chromosome involved in the ABCR. Four out of five
ABCR with a genomic imbalance occurred de novo: one
rare pericentric inversion, one pericentric inversion of
chromosome 2 considered as a chromosomal variant, and
two reciprocal translocations. Two of the five patients
with a de novo imbalance have a non-syndromic form of
ASD. Our results are concordant with previous studies
reporting that ABCR often hide more complex rearrange-
ments regardless of the type of ABCR, particularly when
they appear de novo [3,4,9,10], and when they are associ-
ated with an abnormal phenotype [3,5,6,8-10]. Of the five
de novo imbalances, three originated on the paternally
inherited chromosome, in agreement with previous stud-
ies showing that male gametogenesis is more susceptible
to such rearrangements [4,6,9].
Four of our patients carry common inversions considered
variants without phenotypic effects. In all cases, the inver-
sion was indeed balanced, confirming that common peri-
centric inversions of chromosomes 2, 5, 9, and Y are not
implicated in abnormal phenotype by imbalances at the
breakpoints, even when they occur de novo [22-24]. In a pa-
tient with a pericentric inversion of chromosome 2, a de
novo deletion occurred on an unrelated chromosome.
Imbalances at the breakpoint region
Duplication of the Wolf-Hirschhorn region
Patient 1, carrying a translocation (4;acro p), has two imbal-
ances, a 541 kb subtelomeric 4p16.3 deletion and a directly
adjacent inverted duplication spanning 4.24 Mb. The 4p16.3
deletion overlaps two previously reported 4p terminal dele-
tions between 200 and 400 kb in phenotypically normal in-
dividuals and can be considered benign [25,26]. The
phenotype of our patient is likely related to the proximal du-
plication, which encompasses the Wolf-Hirschhorn critical
region (WHSCR), with two proposed loci, WHSCR1 and
WHSCR2 (Figure 2). Partial 4p trisomy, including the
WHSCR, is associated with variable clinical manifestations
depending on the size of the duplicated segment. Clinical
features include growth retardation, ID, dysmorphic fea-
tures, and heart and renal abnormalities. Most cases re-
ported thus far were identified cytogenetically and are
therefore very large [27-29]. Six smaller molecularly defined
duplications overlapping the WHSCR have been reported in
the literature (Figure 2). Roselló et al. [30] described a boy
with a 1.1 Mb 4p16.3 duplication presenting with ID, dys-
morphic features, language delay, absence seizures, hyper-
activity, aggressive behavior, and non-specific anomalies on
MRI. He also has a terminal 4p16.3 deletion of 1.3 Mb,
interpreted as benign. A terminal 2.3 Mb duplication of4p16.3 was reported by Carmany et al. [31] in a girl with
mild phenotype, including delayed language development,
borderline normal IQ, mild hypertelorism, and normal
height with advanced bone age. The duplication resulted
from a reciprocal translocation and was associated with a
314 kb deletion of 17q25.3, considered probably benign. A
5 Mb terminal 4p16.2 duplication, very similar to the one
observed in our patient, was identified by Wu et al. [32] in
two individuals from the same family with a t(4;15) trans-
location, a 2-month-old boy and his paternal uncle with
mild ID and poor language. The two subjects shared some
characteristics, including similar facial features, widely
spaced nipples and small penis. Similarly, Schonewolf-
Greulich et al. [33] described a 3 Mb terminal 4p16.3 dupli-
cation in a three-generation family with macrocephaly, tall
stature, speech delay, mild ID, and minor dysmorphic fea-
tures. Finally, two smaller interstitial duplications overlap-
ping the WHSCR have been reported. Hannes et al. [34]
detected an interstitial 4p16.3 duplication of 560 kb encom-
passing both WHSCR1 and WHSCR2 in a male toddler
with developmental and speech delay, hypotonia, seizures,
dysmorphic features, hand malformation, and glaucoma.
The duplication occurred at the breakpoint of an inversion
between 4p16.3 and 4q22; given the severity of his features,
it is possible that the inversion contributes to his phenotype
by disrupting a gene at the breakpoint. A 506 kb duplication
in 4p16.3 involving only WHSCR2 was reported by Cyr
et al. [35] in a 16-month-old boy with some characteristics
of the trisomy 4p syndrome, including psychomotor delay,
prominent glabella, low-set ears, and short neck. Compared
to the patient reported by Hannes et al., the only common
features observed in these individuals were developmental
delay and seizures. Our patient presented with mild ID and
autism, without malformations or seizures. Taken together,
these individuals support the observation that duplications
of the WHSCR result in variable, usually mild, clinical mani-
festations. The most common features include developmen-
tal delay, speech delay, and mild cognitive deficits;
dysmorphic features, when present, are usually mild. ASD
was not mentioned in any of the subjects with 4p16.3 dupli-
cations including the WHSCR or in patients with cytogenet-
ically detectable duplications. In a large CNV study in ASD,
Pinto et al. [36] identified a male with a 4p16.3p16.1 dupli-
cation spanning 9.3 Mb, but he also had a 6.8 Mb
8p23.3p23.1 terminal deletion resulting from a de novo
translocation. ASD has been reported in at least two patients
with Wolf-Hirschhorn syndrome [37,38], suggesting that
overexpressed genes within this region could be responsible
for ID and ASD in our patient.
Inverted duplications with terminal deletions involving
the short arm of chromosome 4 have been rarely re-
ported in the literature [28,39-41]. The majority of rear-
rangements with terminal deletion associated with a
duplication in the same chromosome arm correspond to
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mechanisms have been proposed to explain such rear-
rangements [42]. All involve an intermediate dicentric
chromosome which breaks during meiotic division to
produce a monocentric duplicated and deleted chromo-
some. The first mechanism occurs because of a parental
paracentric inversion: during meiosis pairing, both ho-
mologues create an inversion loop; a crossing over in the
loop leads to the formation of a dicentric chromosome
and a reciprocal acentric chromosome. A subsequent
breakage of the dicentric allows the formation of a
monocentric chromosome with the inverted-duplicated-
deleted chromosome. The second mechanism occurs
through non-allelic homologous recombination between
inverted segmental duplications in the same arm. For
both mechanisms, the inverted duplicated region and
the deleted region appear separated by a single copy re-
gion. The third mechanism, which is probably the most
frequent, involves U-type exchange between the sister
chromatids; in this case, the duplicated and deleted re-
gions are adjacent and not separated by a single copy re-
gion [43,44]. In the patient reported here, there is no
single copy region between the deletion and duplication,
suggesting a U-type exchange mechanism. Moreover, as
a telomere capture mechanism is frequently used for sta-
bilizing the broken chromosome ends [44], we suggest
that the translocation between the short arm of an acro-
centric chromosome and the derivative chromosome 4
was generated to stabilize it.
18p11.22p11.31 deletion
In patient 2, with a de novo translocation (5;18), we
identified an interstitial deletion of 4.22 Mb in the
18p11.22p11.31 region. The 18p deletion syndrome, associ-
ated with terminal deletions of variable size, is character-
ized by typical facial features, growth retardation, and ID
[45]. Our patient does not have any dysmorphic features or
growth retardation. Pure interstitial deletions in this region
have not been reported in the literature so far. The DE-
CIPHER and ISCA databases include several patients with
partially overlapping interstitial deletions of variable sizes
(Figure 3); although several are inherited from a normal
parent, two are de novo, a 9 Mb deletion in a patient with
autism (290283) and a 3 Mb deletion (286638, no pheno-
type information). The deletion in patient 2 overlaps 24
known genes; only 1 has a disease-associated OMIM entry,
NDUFV2, involved in autosomal recessive mitochondrial
complex I deficiency characterized by early-onset cardio-
myopathy and encephalopathy. We speculate that haploin-
sufficiency of one or more genes included in the deletion
could be implicated in the ASD phenotype. Two genes in
the region have a high haploinsufficiency score, EPB41L3
and ANKRD12, both highly expressed in brain. EPB41L3
encodes band 4.1-like protein 3 (also known as protein4.1B), which interacts with the synaptic cell adhesion mol-
ecule 1 (SynCAM1) to recruit NMDA receptors to synap-
ses [46], and also acts as tumor suppressor. ANKRD12
(ankyrin repeat domain 12) is a member of the ankyrin
repeats-containing cofactor family, which can inhibit the
transcriptional activity of nuclear receptors through the re-
cruitment of histone deacetylases.
2q37 terminal deletion
Patient 4 carries a maternal inv(2)(q14.2q37.3) with a
terminal 2q37.3 deletion and a 2q14.1q14.2 duplication
at the inversion breakpoints, which arose from a recom-
bination event between the normal and inverted homo-
logues 2 on maternal meiosis 1, followed by breakage of
a dicentric chromosome [15]. The deletion involves the
region implicated in the 2q37 deletion syndrome, fre-
quently associated with ASD [38,47]. His phenotype is
similar to that reported in patients with terminal 2q de-
letions and includes autism, ID, language delay, growth
retardation, and mild facial dysmorphism. Haploinsuffi-
ciency of the HDAC4 gene is responsible for brachyme-
taphalangy and ID [48], but the contribution of one or
more distal genes cannot be excluded since individuals
with distal deletions not including HDAC4 have been
reported with ID, ASD, and seizures. The 2q14.1q14.2
duplication includes 20 genes; no similar imbalances are
reported in DECIPHER, ISCA, or the Database of
Genomic Variants (DGV) so its clinical significance is
unknown. Five smaller duplications with a common du-
plicated region of 440 kb (chr2:120,126,884-120,567,392)
have been reported in DECIPHER; four are inherited from
normal parents (one unknown inheritance), suggesting
that they are probably benign.
Imbalances on unrelated chromosomes
In patient 3, the de novo pericentric chromosome 11 in-
version was not associated with a genomic imbalance
but the SNP array analysis revealed a 7q21.3q22.1 de
novo deletion of 4.9 Mb encompassing over 100 genes.
In this interval, only AP1S1 has been implicated in a
neurological phenotype, a recessive disorder of copper
metabolism. No similar deletions have been reported in
the literature although several cases in DECIPHER and
ISCA have smaller or larger deletions. Two inherited ap-
parently balanced rearrangements mapping to this re-
gion have been reported in autism: a paracentric
inversion (7q22.1q31.1) in two siblings with autism [49]
and a translocation involving chromosome 7q22.1, just
distal to NPTX2, in a subject with autism and ID [50].
Patient 5 has a pericentric inversion of chromosome 2,
which is considered a benign cytogenetic variant. No CNV
was observed in chromosome 2 but the SNP array identi-
fied a de novo 9p24.2 deletion interrupting the RFX3 gene.
A 440 kb deletion including RFX3 was observed in one
Figure 3 18p11.31-p11.22 deletion in patient 2. Map of chromosome 18 (2,500,000-11,700,000, hg19) showing the rearrangement detected in
patient 2 and overlapping deletions from the DECIPHER (D) and ISCA (I) databases. The deletions are represented with horizontal red lines. RefSeq
genes are indicated in blue. The phenotype is indicated when available. The + sign indicates additional morphological features. Two genes within
the deleted region in patient 2 with a high haploinsufficiency score are indicated in orange. Most of the deletions in the distal region are
inherited, usually from normal parents, whereas two other de novo deletions as well as one inherited from a parent with a similar phenotype
overlap the proximal region, highlighted in peach. DD, developmental delay; dn, de novo; ID, intellectual disability; inh, inherited; mat, maternal;
pat, paternal; unk, unknown inheritance.
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this finding, Sahoo et al. [52] analyzed 38,779 individuals
referred for microarray testing and identified seven dele-
tions encompassing the RFX3 gene, with sizes ranging
from 177 kb to 3.5 Mb. Two deletions were de novo, two
paternal, and three of unknown origin. The clinical features
included autism, ID, and behavioral problems. In addition,
one DECIPHER patient (248290) has a partial deletion of
RFX3 but she also carries two large deletions in other chro-
mosomes (no inheritance or phenotype information avail-
able). A similar deletion was reported in a patient from
ISCA (nssv580652) with cataract and global developmental
delay (unknown inheritance). DGV lists only one coding
exon deletion (nsv892090), identified among 6533 Asians
from the general population. Distal deletions of 9p of vary-
ing sizes are characterized by ID, trigonocephaly, dys-
morphic facial features, and genital abnormalities; autism
or autistic-like behavior are also common [53]. Two critical
regions have been proposed for the 9p deletion syndrome,
between 11 Mb and 16 Mb, and the first 2 Mb of 9pter
[53], neither of which includes RFX3 (located at 3.2 Mb).
RFX3 encodes a transcription factor required for ciliogen-
esis in mammals [54]. Many ciliopathy genes, such as those
involved in Joubert syndrome, can present with neurodeve-
lopmental phenotypes, including ID and ASD. Rfx3−/−
mice show several hallmarks of ciliopathies, including left-right asymmetry defects, hydrocephalus, and corpus callo-
sum agenesis; the phenotype of heterozygous mice was not
reported [55,56]. Although the clinical significance of the
RFX3 deletion identified in our patient is unknown, the re-
sults on Rfx3 mutant mice and the presence of rare RFX3
deletions in patients with ID or abnormal behavior suggest
that further studies are warranted on the contribution of
RFX3 loss of function to abnormal brain development.
Conclusions
In this study, we used genome-wide microarray analysis
to elucidate the molecular complexity of microscopically
balanced chromosome rearrangements in a series of 18
patients with ASD. We detected de novo imbalances re-
lated to the initial ABCR or occurring elsewhere in the
genome in 22%. This work provides additional evidence
that ABCR are often more complex than they appear at
first and can hide cryptic rearrangements involved in the
abnormal phenotype regardless of the type and inherit-
ance of the rearrangement. Thus, ABCR associated with
abnormal phenotype have to be analyzed with genome-
wide molecular cytogenetic techniques in order to ex-
clude imbalances either within or outside the initial
breakpoints. In the patients where a genomic imbalance
was not detected by array analysis, higher resolution
techniques based on next-generation sequencing [57,58]
Tabet et al. Molecular Autism  (2015) 6:19 Page 13 of 14might be necessary to explore the rearrangement at the
nucleotide level.
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